IO102-IO103: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขBased on 10 community reports
- โขStacking patterns detailed below
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Access and Availability | IO102-IO103 is an investigational peptide vaccine available only through clinical trials. The Phase 3 IOB-013/KN-D18 study evaluated the vaccine in combination with pembrolizumab for first-line melanoma treatment. | IO102-IO103 is not available outside of clinical trials. Melanoma and cancer patient communities discuss the vaccine in the context of expanding immunotherapy options, particularly its notable efficacy in PD-L1-negative patients who typically respond poorly to checkpoint inhibitors alone. | high The peptide vaccine approach is distinct from both checkpoint inhibitors and personalized neoantigen vaccines. Community interest centers on its off-the-shelf availability (no patient-specific manufacturing) and strong subgroup results. |
Compare these community approaches with published research findings.
Sources
- Melanoma Research Foundation|Clinical trial and immunotherapy discussions(accessed 2026-02-18)
Community Evidence Overview#
IO102-IO103 is an investigational off-the-shelf peptide cancer vaccine targeting IDO and PD-L1, being developed by IO Biotech. It is not available for purchase or self-administration. Community evidence comes from melanoma patient advocacy groups and oncology patient forums.
The strongest community interest surrounds IO102-IO103's Phase 3 results in PD-L1-negative melanoma patients, where the median PFS was 16.6 months vs 3.0 months with pembrolizumab alone. This subgroup typically has limited treatment options and poor outcomes with standard immunotherapy.
Access Information#
IO102-IO103 is currently available only through:
- Clinical trials by IO Biotech (Phase 3 completed in melanoma, additional trials in NSCLC and HNSCC)
- Clinical trial information: ClinicalTrials.gov (search "IO102" or "IO Biotech")
- Note: The Phase 3 IOB-013 trial did not meet its statistical threshold for the ITT population; BLA submission was not recommended based on current data
Patient Community Perspectives#
- Interest in peptide vaccines as a complement to checkpoint inhibitors
- Hope for PD-L1-negative patients with limited current options
- Questions about the distinction between off-the-shelf peptide vaccines and personalized neoantigen approaches
- Discussion of the 5-year follow-up data showing durable responses in earlier-phase trials
- Awareness that Phase 3 did not reach statistical significance for primary endpoint
Important Caveats#
- IO102-IO103 is NOT approved by any regulatory authority as of February 2026
- Phase 3 did not meet its primary statistical endpoint in the overall population
- It is not available outside of clinical trials
- Cancer treatment should always be conducted under oncologist supervision
- Do not attempt to obtain investigational drugs from unauthorized sources
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.